“Some indicators are not objective… We need to be aware of the limitations of antibody therapy”
(Seoul = Yonhap News) Reporter Gye Seung-hyun = The Federation of Health and Medical Organizations (hereinafter referred to as the Federation of Health and Medical Organizations) to realize the right to health[068270] He urged to transparently disclose the clinical data of the novel coronavirus infection (Corona 19) antibody treatment’Rekironaju’.
The Federation of Health and Medical Organizations said, “There is still no transparent and clear information disclosure even when the results of phase 2 clinical (Celltrion antibody treatment) have been announced.” “Some of the evaluation indicators of phase 2 were not disclosed at all, and the criteria for developing severe disease. They pointed out that the indicators that were taken as are not objective.”
They emphasized that “All that has been known so far is a brief press release by Celltrion and the presentation of a conference on clinical trials in Rekirona,” and emphasized that “a paper with peer review must be published in order to prove the research results transparently and scientifically.”
(Incheon = Yonhap News) Reporter Seung-Doo Kim = Prime Minister Jeong Sye-gyun visits Incheon Celltrion Plant 2, which is developing an antibody treatment for a novel coronavirus infection (Corona 19) on December 22, 2020, and listens to the explanation of the treatment from Celltrion Chairman Seo Jeong-jin. [email protected]
According to the results of the Ministry of Food and Drug Safety’s COVID-19 treatment verification advisory meeting results announced on the day, the statistically significant difference between the Corona 19 virus negative time (the time at which the virus transitions from’positive’ to’negative’) between the Rekirona injection group and the placebo group There was no.
The Association of Health and Medical Organizations argued that “Reckirona has a clear limit in improving the treatment of Corona 19, and antibody treatments from foreign countries have not been effective or proven to be effective for severe patients.”
They said, “However, the government and the ruling party focused on the treatment and neglected the problem of beds and medical personnel. Even now, the government should provide accurate information on the meaning and limitations of the treatment and focus on the core issues of hospital beds and manpower.” Emphasized.
In addition, he added, “There is a clear limit to evaluating the safety and effectiveness of only phase 2 clinical trials in the first place,” he added.
Unauthorized reproduction-redistribution prohibited>
2021/01/18 17:29 sent